This site is intended for healthcare professionals

FDA advisory committee recommends approval of TAK 620 for cytomegalovirus infection.- Takeda

Read time: 1 mins
Last updated:10th Oct 2021
Published:9th Oct 2021
Takeda announced the FDA Antimicrobial Drugs Advisory Committee (AMDAC) voted unanimously to recommend use of TAK 620 (maribavir) for the treatment of refractory cytomegalovirus (CMV) infection and disease with genotypic resistance to ganciclovir, valganciclovir, foscarnet or cidofovir in transplant recipients.
Condition: Cytomegalovirus
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Related news and insights